This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $335,410 to Vaxess Technologies, Inc. to develop a needle-free microneedle array patch (MAP) for delivery of a GLP-1 receptor agonist therapy. The goal is to create a more patient-friendly, shelf-stable, and self-applicable delivery system for this diabetes treatment to improve adherence. The award, granted on September 16, 2024, supports activities to build on Vaxess' prior work demonstrating compatibility of the GLP-1 agonist semaglutide with the MIMIX patch platform. The successful completion of this project is intended to identify lead candidates for further development towards a product that could reduce the global burden of type 2 diabetes and obesity.
Generated 3/4/25, 6:22 AM